Mutual of America Capital Management LLC cut its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Rating) by 5.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 192,599 shares of the biopharmaceutical company's stock after selling 12,146 shares during the period. Mutual of America Capital Management LLC owned 0.14% of Halozyme Therapeutics worth $7,615,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Financial Gravity Asset Management Inc. bought a new stake in shares of Halozyme Therapeutics during the third quarter valued at about $2,220,000. First Horizon Advisors Inc. increased its position in shares of Halozyme Therapeutics by 188.8% during the second quarter. First Horizon Advisors Inc. now owns 722 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 472 shares during the period. Meeder Asset Management Inc. increased its position in shares of Halozyme Therapeutics by 223.6% during the second quarter. Meeder Asset Management Inc. now owns 741 shares of the biopharmaceutical company's stock valued at $33,000 after buying an additional 512 shares during the period. Brown Brothers Harriman & Co. bought a new stake in shares of Halozyme Therapeutics during the second quarter valued at about $35,000. Finally, Selective Wealth Management Inc. bought a new position in shares of Halozyme Therapeutics in the second quarter worth approximately $44,000. 96.32% of the stock is currently owned by institutional investors.
Get
Halozyme Therapeutics alerts:
Halozyme Therapeutics Stock Performance
NASDAQ:HALO opened at $52.87 on Friday. The firm has a market cap of $7.15 billion, a PE ratio of 35.48, a price-to-earnings-growth ratio of 0.68 and a beta of 1.22. Halozyme Therapeutics, Inc. has a fifty-two week low of $32.00 and a fifty-two week high of $59.46. The company has a debt-to-equity ratio of 15.37, a quick ratio of 5.03 and a current ratio of 5.97. The business has a 50 day moving average price of $55.00 and a 200-day moving average price of $48.50.
Halozyme Therapeutics (NASDAQ:HALO – Get Rating) last released its quarterly earnings data on Tuesday, November 8th. The biopharmaceutical company reported $0.70 earnings per share for the quarter, beating analysts' consensus estimates of $0.49 by $0.21. The firm had revenue of $208.98 million during the quarter, compared to analyst estimates of $187.87 million. Halozyme Therapeutics had a return on equity of 134.71% and a net
margin of 36.37%. Equities research analysts predict that Halozyme Therapeutics, Inc. will post 2.07 earnings per share for the current year.
Insider Buying and Selling
In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the firm's stock in a transaction on Thursday, November 17th. The stock was sold at an average price of $52.15, for a total transaction of $521,500.00. Following the completion of the transaction, the chief executive officer now owns 587,177 shares of the company's stock, valued at $30,621,280.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CFO Nicole Labrosse sold 5,000 shares of the stock in a transaction that occurred on Tuesday, November 15th. The shares were sold at an average price of $53.81, for a total transaction of $269,050.00. Following the sale, the chief financial officer now owns 4,045 shares in the company, valued at $217,661.45. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Helen Torley sold 10,000 shares of the company's stock in a transaction that occurred on Thursday, November 17th. The shares were sold at an average price of $52.15, for a total value of $521,500.00. Following the completion of the transaction, the chief executive officer now directly owns 587,177 shares in the company, valued at $30,621,280.55. The disclosure for this sale can be found here. Insiders sold 85,000 shares of company stock valued at $4,666,350 over the last quarter. 2.30% of the stock is owned by company insiders.
Wall Street Analysts Forecast Growth
HALO has been the topic of several research analyst reports. SVB Leerink decreased their price objective on shares of Halozyme Therapeutics from $62.00 to $61.00 and set an "outperform" rating on the stock in a research report on Wednesday, January 11th. StockNews.com initiated coverage on shares of Halozyme Therapeutics in a research report on Wednesday, October 12th. They issued a "hold" rating on the stock. JMP Securities upped their price objective on shares of Halozyme Therapeutics from $60.00 to $62.00 and gave the stock a "market outperform" rating in a research report on Wednesday, November 9th. Morgan Stanley upped their price objective on shares of Halozyme Therapeutics from $53.00 to $65.00 and gave the stock an "overweight" rating in a research report on Wednesday, December 21st. Finally, JPMorgan Chase & Co. increased their price target on shares of Halozyme Therapeutics from $53.00 to $54.00 and gave the company an "overweight" rating in a research report on Tuesday, November 22nd. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat, Halozyme Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $59.63.
Halozyme Therapeutics Company Profile
(Get Rating)
Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Recommended Stories
- Get a free copy of the StockNews.com research report on Halozyme Therapeutics (HALO)
- Ford Stock Going Forward After Big Earnings Flop
- Nvidia Rallies As Investors Bullish On Chipmaker's AI Business
- Bright Green Corporation Future May be Getting Brighter
- Microsoft Fast Integrating AI Into Enterprise & Healthcare Suites
- Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Rating).
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
